⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 3, 2024

Figure S3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis

Jack Pengfei Tang Pénélope Lafeuille Alexandru Socolov Sheila S. Diamond Jacob Aptekar Theodore B. Moore Esther H. Nie Mark R. Hanudel Theodore S. Nowicki

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Figure S3. ICANS incidence and time to symptom onset.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tang et al. (2024) studied this question.

synapsesocial.com/papers/68e55ee7e2b3180350efbe4d https://doi.org/10.1158/2767-9764.27160827

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S4 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
2Figure S5 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
3Figure S1 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
4Figure S2 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
5Figure S8 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024

More related papers

Figure S6 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
Supplemental Table 3 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024
Figure S7 from Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis2024